Logo

Chondrogene Posts Slight Decline in Q1 Revenue Amid Surge in R&D Spending, Net Loss

May 31, 2006

NEW YORK, May 31 (GenomeWeb News) - Chondrogene's first-quarter revenue declined around 1 percent as R&D spending surged 85 percent and net losses 26.5 percent year over year, the company reported today.

 

Total receipts for the three months ended March 31 declined to CA$868,222 ($788,312) from CA$878,251 year over year.

 

Though the brunt of the total receipts were from a one-time payment from Pfizer that was unchanged from the first quarter 2005, the decline in the current period stemmed from lower fees and service payments, which fell to CA$196,459 in the current quarter from CA$206,488 year over year.

 

Chondrogene said R&D spending swelled to CA$ 2.4 million from CA$1.3 million in the year-ago period.

 

First-quarter net loss jumped to CA$2.2 million from CA$1.1 million year over year.

 

Chondrogene said it had around CA$4.4 million in cash and equivalents as of March 31.

 

Since the quarter ended, Chondrogene closed a CA$25 million private stock placement that will enable the company to "drive commercialization" of its lead product, the ColonSentry test for colon cancer.

Breaking News
The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.